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The Who: A pheochromocytoma, a rare 
catecholamine-secreting tumor derived 
from chromaffin cells. Catecholamines 
released from the tumor  stimulate both 
alpha- and beta-adrenergic receptors.
The Where: Typically an adrenal tumor, 
also associated with syndromes including 
von Hippel-Lindau (VHL) syndrome, 
multiple endocrine neoplasia type 2 (MEN 
2), and neurofibromatosis type I (NF1).
The What: Secretes epinephrine and 
norepinephrine which can precipitate 
life-threatening hypertensive crises 
and cardiac arrhythmias. About 10% 
are malignant, which is defined as the 
presence of metastases.
The How: Surgical resection remains 
the standard treatment of choice.
The Why: A preoperative 
approach to the management of the 
pheochromocytoma patient has yet to 
be standardized. Here we provide an 
anecdotal preoperative outline to the 
management of a hemodynamically 
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Image 2.
Coronal view of CT 
scan showing a 6 cm 
pheochromocytoma.
Image 1. 
Transverse view of CT scan showing 
large right suprarenalmass contiguous 
with the liver. The mass was a 
pheochromocytoma after confirmation 
by elevated 24-hour urinary 
metanephrines.
Image 3. 
Timeline of preoperative treatment before successful 
removal of a pheochromocytoma.
Preoperative management of the pheochromocytoma 
patient is not well elucidated. This case describes 
a successful sequence of steps taken to ensure 
preoperative hemodynamic stability.
 •  If beta-blockers are used alone, unopposed alpha-
mediated vasoconstriction will occur, thus exacerbating 
hypertension to dangerous levels. Alpha-blockade 
should occur first.
 •  Volume re-expansion is important. Since accelerated 
hypertension will cause pressure natriuresis, large volume 
re-expansion with normal saline solution was achieved. 
However, volume balance should be kept even.
 •  It is important to initiate beta-blockage to stabilize 
heart rate, which may lead to tachyarrhythmias if 
uncontrolled. 
 •  Beta-blockade was then titrated down the day 
before surgery to avoid protracted hypotension as 
vasodilation would follow pheochromocytoma 
removal.
 •  With the concerted efforts of multiple teams including 
endocrinology, nephrology, critical care medicine, 
and surgery, the pheochromocytoma patient may be 
appropriately cared for preoperatively.
A 33-year-old Asian female presented to the emergency department with headaches, flushing, palpitations, diaphoresis, 
and insomnia. She was tachycardiac to 144 and hypertensive to 220/118. She had no previous history of hypertension. 
Orthostatic measurements were also positive as her standing blood pressure was 89/61. Creatinine and troponins were mildly 
elevated. EKG showed sinus tachycardia with 1st-degree AV block and right axis deviation. An abdominal CT revealed a 6 
cm right adrenal mass contiguous with the liver and superior pole of the kidney.  24-hour urine catecholamine measurement 
revealed markedly elevated epinephrine and norepinephrine levels, confirming the diagnosis of pheochromocytoma. Surgery, 
nephrology, and endocrinology services were consulted. The patient was admitted to the intensive care unit due to the labile 
nature of her blood pressure.  Treatment was initiated with phenoxybenzamine 10mg BID along with maintenance intravenous 
fluids of NSS 100 cc/hr. Her blood pressure remained labile on day two, with 74-179 systolic and 65-140 diastolic. She 
was still tachycardic to 110. Fluids were increased to 150cc/hr. On day three, the phenoxybenzamine dose was doubled to 
20mg BID. Her tachycardia did not resolve and on day four, metoprolol 12.5mg BID was added. The patient’s blood pressure 
normalized and remained stable. She was asymptomatic, creatinine returned to baseline, and she was transferred to low-
level monitoring. Her blood pressure was stable at 90-110 systolic and 50-70 diastolic. After achieving hemodynamic stability, 
surgery was scheduled. On day 5, metoprolol was doubled to 25mg BID. This regimen was continued until day 9 when 
metoprolol was taken back down to 12.5mg BID in preparation for surgery. This treatment regimen was continued for 1 more 
day before a successful laparoscopic right adrenalectomy.
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